Published in Proc Natl Acad Sci U S A on October 01, 1996
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol (2011) 3.40
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood (2009) 1.61
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59
Multiple costimulatory modalities enhance CTL avidity. J Immunol (2005) 1.58
Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood (2005) 1.21
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer (2009) 1.17
Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol (2008) 1.04
Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res (2008) 0.94
Chitosan solution enhances the immunoadjuvant properties of GM-CSF. Vaccine (2007) 0.94
Autoreactive responses to an environmental factor. 2. Phthalate-induced anti-DNA specificity is downregulated by autoreactive cytotoxic T cells. Immunology (2004) 0.93
Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Front Oncol (2012) 0.92
Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol (2012) 0.90
Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood (2007) 0.89
A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood (2007) 0.85
CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother (2011) 0.84
Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells. Am J Pathol (1998) 0.84
Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res (2011) 0.84
Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol Immunol (2008) 0.81
Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells. Cancer Immunol Immunother (2010) 0.81
Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas. Vaccine (2007) 0.81
Native IgG2a(b) is barely antigenic to major histocompatibility complex class II-restricted T cells owing to inefficient internalization by professional antigen-presenting cells. Immunology (2000) 0.77
Therapeutic vaccine for lymphoma. Yonsei Med J (2007) 0.77
Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes. Am J Blood Res (2014) 0.77
Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes. J Biomed Biotechnol (2010) 0.76
Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses. World J Clin Oncol (2011) 0.76
Hybridoma-Derived Idiotype Vaccine for Lymphoma: Approval Must Wait. Pharmaceuticals (Basel) (2010) 0.75
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73
Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med (1988) 4.79
Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science (1986) 2.84
Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med (1992) 2.73
Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature (1993) 2.62
Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci U S A (1971) 2.17
Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A (1972) 2.09
Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol (1987) 2.00
Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest (1986) 1.76
Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol (1977) 1.60
Antibodies to idiotypes of isologous immunoglobulins. J Exp Med (1975) 1.56
Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol (1988) 1.46
Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol (1986) 1.39
Induction of secretion of IgM from cells of the B cell line 38c-13 by somatic cell hybridization. J Immunol (1979) 1.32
Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol (1987) 1.28
Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A (1994) 1.17
Gene transfer as cancer therapy. Adv Immunol (1995) 1.17
Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol (1987) 1.08
Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet (1995) 1.03
Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res (1993) 1.03
Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function. J Immunol (1990) 0.99
Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol (1990) 0.96
Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol (1988) 0.96
Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J Immunol (1988) 0.95
Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev (1995) 0.93
Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice. J Exp Med (1974) 0.91
Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. J Natl Cancer Inst (1976) 0.86
Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J Immunol (1983) 0.86
Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. J Natl Cancer Inst (1990) 0.85
Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315. Scand J Immunol (1980) 0.84
Differential modulation of surface antigens on human macrophages by IFN-gamma and GM-CSF: effect on susceptibility to LAK lysis. J Leukoc Biol (1991) 0.82
Participation of the humoral immune system in the myeloma-specific transplantation resistance. J Immunol (1978) 0.81
Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy. Blood (1991) 0.81
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature (2000) 8.96
The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature (1981) 8.44
Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 7.52
Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci U S A (1981) 5.51
CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci U S A (1989) 5.07
Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus. J Virol (1980) 4.63
Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood (2000) 4.34
Identification of a sarcoma virus-coded phosphoprotein in nonproducer cells transformed by Kirsten or Harvey murine sarcoma virus. Virology (1979) 4.08
Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol (2000) 3.46
p21 of Kirsten murine sarcoma virus is thermolabile in a viral mutant temperature sensitive for the maintenance of transformation. J Virol (1979) 2.94
Pathogen-specific loss of host resistance in mice lacking the IFN-gamma-inducible gene IGTP. Proc Natl Acad Sci U S A (2000) 2.80
Intracellular localization of human monocyte associated interleukin 1 (IL 1) activity and release of biologically active IL 1 from monocytes by trypsin and plasmin. J Immunol (1986) 2.40
Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol (1999) 2.38
Steroid induction of mouse mammary tumor virus: effect upon synthesis and degradation of viral RNA. J Virol (1977) 2.26
Interaction of NF-kappaB and NFAT with the interferon-gamma promoter. J Biol Chem (1997) 2.15
Interleukin-1 costimulatory activity on the interleukin-2 promoter via AP-1. Science (1989) 2.01
The interleukin 2 CD28-responsive complex contains at least three members of the NF kappa B family: c-Rel, p50, and p65. Proc Natl Acad Sci U S A (1993) 1.98
Different rat-derived transforming retroviruses code for an immunologically related intracellular phosphoprotein. Proc Natl Acad Sci U S A (1979) 1.98
Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor-mediated activation. Eur J Immunol (1989) 1.88
Heteroduplex analysis of cloned rat endogenous replication-defective (30 S) retrovirus and Harvey murine sarcoma virus. Virology (1980) 1.81
Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut (2006) 1.77
Mammary tumor virus induction by glucocorticoids. Characterization of specific transcriptional regulation. J Biol Chem (1975) 1.76
Biochemical and physiological mechanisms in glucocorticoid hormone induction of mouse mammary tumor virus. Virology (1976) 1.74
The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature (2001) 1.71
IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol (1999) 1.71
Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol (2000) 1.68
Expression of ets genes in mouse thymocyte subsets and T cells. J Immunol (1989) 1.65
Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol (2001) 1.59
Two essential regulatory elements in the human interferon gamma promoter confer activation specific expression in T cells. J Exp Med (1993) 1.57
In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur J Immunol (2000) 1.57
Differential inhibition of IL-1 and TNF-alpha mRNA expression by agents which block second messenger pathways in murine macrophages. J Immunol (1988) 1.55
Physical map of the Kirsten sarcoma virus genome as determined by fingerprinting RNase T1-resistant oligonucleotides. J Virol (1978) 1.53
Kappa B site-dependent activation of the interleukin-2 receptor alpha-chain gene promoter by human c-Rel. Mol Cell Biol (1992) 1.52
One-signal requirement for interferon-gamma production by human large granular lymphocytes. J Immunol (1987) 1.49
The c-rel protooncogene product c-Rel but not NF-kappa B binds to the intronic region of the human interferon-gamma gene at a site related to an interferon-stimulable response element. Proc Natl Acad Sci U S A (1992) 1.49
Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production. Mol Cell Biol (1998) 1.48
Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest (2001) 1.43
The successful use of cardiopulmonary support for a transected bronchus. Perfusion (2011) 1.42
Cloning and functional characteristics of murine large granular lymphocyte-1: a member of the Ly-49 gene family (Ly-49G2) J Exp Med (1995) 1.35
Glucocorticoid-receptor interaction and induction of murine mammary tumor virus. J Biol Chem (1975) 1.34
Complete migration of ventriculoperitoneal shunt into the ventricle: report of two cases. Neurosurgery (1983) 1.33
Interleukin-3 withdrawal induces an early increase in mitochondrial membrane potential unrelated to the Bcl-2 family. Roles of intracellular pH, ADP transport, and F(0)F(1)-ATPase. J Biol Chem (2000) 1.29
Interleukin 2-induced proliferation of murine natural killer cells in vivo. J Exp Med (1990) 1.28
The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element. Mol Cell Biol (1996) 1.26
Interleukin 2 induction of pore-forming protein gene expression in human peripheral blood CD8+ T cells. J Exp Med (1990) 1.22
A cyclophilin-related protein involved in the function of natural killer cells. Proc Natl Acad Sci U S A (1993) 1.17
Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. J Immunol (1991) 1.17
Analysis of T cell receptors in highly purified rat and human large granular lymphocytes (LGL): lack of functional 1.3 kb beta-chain mRNA. J Immunol (1986) 1.14
Negative transcriptional regulation of the interferon-gamma promoter by glucocorticoids and dominant negative mutants of c-Jun. J Biol Chem (1995) 1.13
Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta. J Natl Cancer Inst (1988) 1.12
Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol (2001) 1.11
Detection of c-rel-related transcripts in mouse hematopoietic tissues, fractionated lymphocyte populations, and cell lines. Mol Cell Biol (1987) 1.11
IL-2 and IL-6 synergize to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells. J Immunol (1990) 1.09
Cellular and molecular mechanisms of IFN-gamma production induced by IL-2 and IL-12 in a human NK cell line. J Leukoc Biol (1995) 1.09
Three-dimensional structure of α-crystallin domain dimers of human small heat shock proteins HSPB1 and HSPB6. J Mol Biol (2011) 1.09
Direct evidence for an intracellular role for IFN-gamma. Microinjection of human IFN-gamma induces Ia expression on murine macrophages. J Immunol (1990) 1.08
Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res (1990) 1.08
Lack of gene rearrangement and mRNA expression of the beta chain of the T cell receptor in spontaneous rat large granular lymphocyte leukemia lines. J Exp Med (1985) 1.07
IL-13 production by NK cells: IL-13-producing NK and T cells are present in vivo in the absence of IFN-gamma. J Immunol (1999) 1.07
The flavonoid baicalin inhibits superantigen-induced inflammatory cytokines and chemokines. FEBS Lett (2001) 1.07
Role of a STAT binding site in the regulation of the human perforin promoter. J Immunol (1999) 1.07
Comparative studies of CD3- and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol (1991) 1.07
Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. Eur J Immunol (2000) 1.06
Differential regulation of the Janus kinase-STAT pathway and biologic function of IL-13 in primary human NK and T cells: a comparative study with IL-4. J Immunol (1998) 1.02
Differential regulation of chemokine gene expression by 15-deoxy-delta 12,14 prostaglandin J2. J Immunol (2001) 1.02
Cytokine gene expression during the generation of human lymphokine-activated killer cells: early induction of interleukin 1 beta by interleukin 2. Cancer Res (1989) 1.02
Expression of RNA of an endogenous replication-defective retrovirus in rat mammary adenocarcinomas induced by 7,12-dimethylbenz[a]anthracene. J Natl Cancer Inst (1978) 1.02
Ca2+-dependent production and release of IL-8 in human neutrophils. J Immunol (1998) 1.02
Characterization of a silencer regulatory element in the human interferon-gamma promoter. J Biol Chem (1994) 1.02
Detection of IL-1 alpha and IL-1 beta gene expression by in situ hybridization. Tissue localization of IL-1 mRNA in the normal C57BL/6 mouse. J Immunol (1988) 1.02
Identification of enhancer-like elements in human IFN-gamma genomic DNA. J Immunol (1990) 1.02
Chromium(VI)-induced nuclear factor-kappa B activation in intact cells via free radical reactions. Carcinogenesis (1995) 1.01
Posttranscriptional control of human gamma interferon gene expression in transfected mouse fibroblasts. Mol Cell Biol (1986) 0.99
Expression of transfected human interferon-gamma DNA: evidence for cell-specific regulation. J Immunol (1986) 0.99
Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes. Cancer Res (1991) 0.98
Induction of c-fos and c-myc expression in T lymphocytes after treatment with recombinant interleukin 1-alpha. J Immunol (1986) 0.97
Functional reconstitution and regulation of IL-18 activity by the IL-18R beta chain. J Immunol (2001) 0.96
Rat sarcoma virus: further analysis of individual viral isolates and the gene product. J Virol (1981) 0.96
Human B cell activation by autologous NK cells is regulated by CD40-CD40 ligand interaction: role of memory B cells and CD5+ B cells. J Immunol (2001) 0.96
Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood (1992) 0.96
A single nucleotide polymorphism in the proximal IFN-gamma promoter alters control of gene transcription. Genes Immun (2002) 0.95
Delayed traumatic intracerebral hematoma: report of 15 cases operatively treated. Neurosurgery (1984) 0.94
A model of human cytokine regulation based on transfection of gamma interferon gene fragments directly into isolated peripheral blood T lymphocytes. J Exp Med (1990) 0.94
Induction of T cell differentiation and lymphomagenesis in the thymus of mice with severe combined immune deficiency (SCID). J Immunol (1994) 0.94
HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum (2001) 0.94
Characterization of cytokine differential induction of STAT complexes in primary human T and NK cells. J Leukoc Biol (1998) 0.94
Eosinophilic angiocentric fibrosis and Wegener's granulomatosis: a case report and literature review. J Clin Pathol (2001) 0.92
Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. Cancer Res (1987) 0.92
Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. J Immunol (1992) 0.92
Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst (1995) 0.92
Activating Ly-49 NK receptors: central role in cytokine and chemokine production. J Immunol (2001) 0.92
IL-7 regulation of cytotoxic lymphocytes: pore-forming protein gene expression, interferon-gamma production, and cytotoxicity of human peripheral blood lymphocytes subsets. Cell Immunol (1991) 0.92
Activation of nuclear factor of activated T cells in a cyclosporin A-resistant pathway. J Biol Chem (1996) 0.91
The absence of Harvey ras mutations during development and progression of squamous cell carcinomas of the head and neck. Br J Cancer (1993) 0.91
Identification of a DNA binding site for the nuclear factor YY1 in the human GM-CSF core promoter. Nucleic Acids Res (1994) 0.90
Structural basis of bacterial defense against g-type lysozyme-based innate immunity. Cell Mol Life Sci (2012) 0.90
Mucosa-specific targets for regulation of IFN-gamma expression: lamina propria T cells use different cis-elements than peripheral blood T cells to regulate transactivation of IFN-gamma expression. J Immunol (2000) 0.90
IL-1 is an autocrine growth factor for T cell clones. J Immunol (1988) 0.90